![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Drug delivery systems are a promising technology to increase poor solubility and bioavailability of compounds. Therefore we have developed PLGA-PEG encapsulated amphotericin B nanoparticles (NPs) drug delivery technology to increase the solubility of amphotericin B and target the macrophage of infected tissues during visceral leishmaniasis. The structural characterization by transmission electron microscopy and dynamic light scattering revealed the nano-size of the particle (30–35 nanometers). Fourier transform infrared spectroscopy confirmed the PLGA-PEG encapsulation. The mean cytotoxic assay (0.0803 + 0.0253) of extracellular promastigote of PLGA-PEG encapsulated amphotericin B is significantly lower than that of amphotericin B (0.1134 + 0.0153) and inhibition of amastigotes in the splenic tissue was significantly more than with conventional amphotericin B (93.02 + 6.63 versus 74.42 +14.78). Amphotericin B encapsulated PLGA-PEG nanoparticles were found to be more effective than free amphotericin B in terms of therapeutic efficacy during in vitro and in vivo study.
Acknowledgment
We acknowledge Indian Council of Medical Research, India for finanicial support. We acknowledge Dr. Geeta Jotwani, Manas Ranjan Dikhit, Dr. Sindhuprava Rana, Md. Yousuf Ansari, Dr. Ravi, Gaurav Kumar, Dr. Vahab Ali, Rani Mansuri, Kalyani Trivedi, Zahra Bandi, Sahil Sinha and Mukta Rani for their scientific and moral supports.
Declaration of interest
The authors are thankful to Indian Council of medical research, for providing financial support for carrying out nanomedicine related research work in our institute. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.